Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Total Current Liabilities: 2017-2024

Historic Total Current Liabilities for Arcus Biosciences (RCUS) over the last 8 years, with Dec 2024 value amounting to $226.0 million.

  • Arcus Biosciences' Total Current Liabilities rose 9.30% to $235.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $235.0 million, marking a year-over-year increase of 9.30%. This contributed to the annual value of $226.0 million for FY2024, which is 22.83% up from last year.
  • Per Arcus Biosciences' latest filing, its Total Current Liabilities stood at $226.0 million for FY2024, which was up 22.83% from $184.0 million recorded in FY2023.
  • In the past 5 years, Arcus Biosciences' Total Current Liabilities registered a high of $226.0 million during FY2024, and its lowest value of $121.7 million during FY2020.
  • Moreover, its 3-year median value for Total Current Liabilities was $193.0 million (2022), whereas its average is $201.0 million.
  • Per our database at Business Quant, Arcus Biosciences' Total Current Liabilities soared by 435.85% in 2020 and then declined by 4.66% in 2023.
  • Over the past 5 years, Arcus Biosciences' Total Current Liabilities (Yearly) stood at $121.7 million in 2020, then spiked by 36.44% to $166.0 million in 2021, then rose by 16.27% to $193.0 million in 2022, then dropped by 4.66% to $184.0 million in 2023, then climbed by 22.83% to $226.0 million in 2024.